

# Safety Data Sheet

## Donepezil Hydrochloride Orally Disintegrating Tablets

**Strength:** 5 mg and 10 mg **Pack Size:** 30/90/100/500/1000 tablets per bottle  
and 10 X 10 unitdose blisters

**Revision No.:** 02

### EMERGENCY OVERVIEW

Each Donepezil hydrochloride orally disintegrating tablet intended for oral administration contains 5 mg or 10 mg of donepezil hydrochloride and excipients considered nontoxic and nonhazardous in small quantities and under conditions of normal occupational exposure.


### Section 1. Identification

#### Identification of the product

**Product name:** Donepezil Hydrochloride Orally Disintegrating Tablets

**Formula:** C<sub>24</sub>H<sub>29</sub>NO<sub>3</sub>HCl

**Chemical Name:** (±)-2, 3-dihydro-5, 6-dimethoxy-2-[[1-(phenylmethyl)-4-piperidinyl]methyl]-1*H*-inden-1-one hydrochloride



**Donepezil Hydrochloride**

#### Manufacturer / supplier identification

**Company:** Cadila Healthcare Ltd. Ahmedabad, India

**Address:** Sarkhej – Bavla N.H. 8A, Moraiya. Tal. Sanand.  
Dist. Ahmedabad - 382210. State: Gujarat. India

**Contact for information:** Tel.: +91 79 6868100 Fax: +91 79 3750319

**Emergency Telephone No.** Tel.: +91 79 6868100

**Recommended use /  
Therapeutic Category** Anticholinesterase Inhibitor

**Restriction on Use /  
Contraindications:** Donepezil hydrochloride orally disintegrating tablets are contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives.

**Safety Data Sheet**  
**Donepezil Hydrochloride Orally Disintegrating Tablets**

**Strength:** 5 mg and 10 mg **Pack Size:** 30/90/100/500/1000 tablets per bottle  
and 10 X 10 unitdose blisters

**Revision No.:** 02

**Section 2. Hazard(s) Information**

<b>Dose and Administration</b>	<b>Mild to Moderate Alzheimer's disease</b> – 5 mg or 10 mg administered once daily <b>Severe Alzheimer's disease</b> - 10 mg administered once daily
<b>Adverse Effects</b>	<b><i>Adverse Events Leading to Discontinuation</i></b> Nausea, Diarrhea ,Vomiting <b><i>Most Frequent Adverse Events Seen in Association with the Use of Donepezil Hydrochloride</i></b> Insomnia , muscle cramp, fatigue and anorexia <b>Adverse Events Reported in Controlled Clinical Trials in Mild to Moderate Alzheimer's Disease</b> <b>Body as a Whole</b> Headache Pain, various locations Accident Fatigue <b>Cardiovascular System</b> Syncope <b>Digestive System</b> Nausea ,Diarrhea ,Vomiting ,Anorexia <b>Hemic and Lymphatic System</b> Ecchymosis <b>Metabolic and Nutritional Systems</b> Weight Decrease <b>Musculoskeletal System</b> Muscle Cramps Arthritis <b>Nervous System</b> Insomnia ,Dizziness ,Depression Abnormal Dreams ,Somnolence <b>Urogenital System</b> Frequent Urination  <b>Adverse Events Reported in Controlled Clinical Trials in Severe Alzheimer's Disease</b> <b>Body as a Whole</b> Accident Infection, Headache Pain ,Back Pain, Fever Chest Pain <b>Cardiovascular System</b> Hypertension ,Hemorrhage ,Syncope <b>Digestive System</b> Diarrhea ,Vomiting ,Anorexia ,Nausea <b>Hemic and Lymphatic System</b> Ecchymosis <b>Metabolic and Nutritional Systems</b> Creatine Phosphokinase Increased Dehydration, Hyperlipemia <b>Nervous System</b> Insomnia ,Hostility ,Nervousness ,Hallucinations Somnolence ,Dizziness, Depression ,Confusion ,Emotional Lability Personality Disorder <b>Skin And Appendages</b> Eczema <b>Urogenital System</b> Urinary Incontinence
<b>Over Dose Effect</b>	Severe nausea, vomiting, salivation, sweating, bradycardia, hypotension, respiratory depression, collapse and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved.
<b>Medical Conditions</b>	Patient should inform the doctor about all the present or past health problems. Include:

# Safety Data Sheet

## Donepezil Hydrochloride Orally Disintegrating Tablets

**Strength:** 5 mg and 10 mg **Pack Size:** 30/90/100/500/1000 tablets per bottle and 10 X 10 unitdose blisters

**Revision No.:** 02

Any heart problems including problems with irregular, slow, or fast, heartbeats ,Asthma or lung problems , seizure ,Stomach ulcers ,Difficulty passing urine ,Liver or kidney problems,Present pregnancy or plans to become pregnant. It is not known if donepezil hydrochloride can harm an unborn baby. ,Present breast-feeding. It is not known if donepezil hydrochloride passes into breast milk. Donepezil hydrochloride is not for women who are breast-feeding.

Patient should inform the doctor about all the medicines the patient takes, including prescription and non-prescription medicines, vitamins, and herbal products.Donepezil hydrochloride and other medicines may affect each other.

Patient should inform the doctor if the patient takes aspirin or medicines called nonsteroidal anti-inflammatory drugs (NSAIDs). There are many NSAID medicines, both prescription and non-prescription. Ask the doctor or pharmacist if you are not sure if any of the patient's medicines are NSAIDs. Taking NSAIDs and donepezil hydrochloride together may make the patient more likely to get stomach ulcers.

Donepezil hydrochloride taken with certain medicines used for anesthesia may cause side effects. Tell the responsible doctor or dentist that the patient takes donepezil hydrochloride before the patient has: surgery ,medical procedures ,dental surgery or procedures.

Know the medicines that the patient takes. Keep a list of all the patient's medicines. Show it to the doctor or pharmacist before the patient starts a new medicine.

### Contraindications

Donepezil hydrochloride orally disintegrating tablets are contraindicated in patients with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives.

### Pregnancy Comments

There are no adequate or well-controlled studies in pregnant women. Donepezil hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### Pregnancy Category

Category C

## Section 3. Composition / information on ingredients

### Component

### Exposure Limit

### CAS No.

### Principle Component :

Donepezil hydrochloride

Not Found

120011-70-3

### Inactive Ingredients :

**Safety Data Sheet**  
**Donepezil Hydrochloride Orally Disintegrating Tablets**

**Strength:** 5 mg and 10 mg **Pack Size:** 30/90/100/500/1000 tablets per bottle  
 and 10 X 10 unitdose blisters

**Revision No.:** 02

Ammonium glycyrrhizate	Not Found	53956-04-0
Colloidal silicon dioxide	Not Found	7631-86-9
Crospovidone	Not Found	9003-39-8
Flavor firmenich powder Peppermint	Not Found	8006-90-4
Flavor strawberry	Not Found	NA
Magnesium stearate	Not Found	577-04-0
Mannitol	Not Found	69-65-8
Sucralose	Not Found	56038-13-2

**Section 4. First-aid measures**

**General**

**Skin Contact:** Wash contaminated area with soap and water.  
**Eye Contact:** Flush with running water for 15 minutes holding eyelids open.  
**Inhalation:** No specific treatment is necessary since this product is not likely to be hazardous by inhalation if tablet is left intact.  
**Ingestion:** Get medical attention immediately; induce vomiting if victim is conscious

**Overdose Treatment**

Tertiary anticholinergics such as atropine may be used as an antidote for donepezil hydrochloride overdose. Intravenous atropine sulfate titrated to effect is recommended: an initial dose of 1.0 to 2.0 mg IV with subsequent doses based upon clinical response. Atypical responses in blood pressure and heart rate have been reported with other cholinomimetics when co-administered with quaternary anticholinergics such as glycopyrrolate.

**Section 5. Fire -fighting measures**

<b>Flash point</b>	Not Found	<b>Upper Flammable Limit:</b>	Not Found
<b>Auto-Ignition Temperature:</b>	Not Found	<b>Lower Flammable Limit:</b>	Not Found
<b>Extinguishing Media</b>	Water Spray, dry chemical, carbon dioxide or foam as appropriate for surrounding fire and	<b>Fire and Explosion Hazard</b>	This material is assumed to be combustible. As with all dry powders

# Safety Data Sheet

## Donepezil Hydrochloride Orally Disintegrating Tablets

**Strength:** 5 mg and 10 mg **Pack Size:** 30/90/100/500/1000 tablets per bottle and 10 X 10 unitdose blisters

**Revision No.:** 02

material.

it is advisable to ground

mechanical equipment in contact with the dry material to dissipate the potential build up of static electricity.

**Fire Fighting Procedure** As with all fires, evacuate personnel to a safe area. Fire fighter should use self- contained breathing equipment and protective clothing.

### Section 6. Accidental Release Measures

**Spill Response** Wear approved respiratory protection, chemically compatible gloves and protective clothing. Wipe up spillage or collect spillage using high efficiency vacuum cleaner. Avoid breathing dust. Place spillage in appropriately labelled container for disposal. Wash spill site.

### Section 7. Handling and Storage

**Storage** Store at 20° to 25°C (68° to 77°F)  
Dispense in a tight container.

**Incompatibility** No Data available

### Section 8. Exposure controls and personal protection

**Respiratory Protection** Protection from inhalation is not normally necessary. If ventilation is inadequate or dust is likely to generate, use of suitable dust mask would be appropriate.

**Skin Protection** Skin protection is not normally necessary, however it is good practice to avoid contact with chemical to use suitable gloves when handling.

**Eye protection** Eye protection is not normally necessary. If concerned wear protective goggles or glasses. Wash hands prior to touching eye and in particular handling contact lenses.

**Protective Clothing** Protective clothing is not normally necessary, however it is good practice to use apron.

**OSHA - Final PELs  
- Table Z-3 Mineral D:** (80)/(% SiO<sub>2</sub>) mg/m<sup>3</sup> TWA-20 mppcf

**Engineering Controls:** Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below

# Safety Data Sheet

## Donepezil Hydrochloride Orally Disintegrating Tablets

**Strength:** 5 mg and 10 mg **Pack Size:** 30/90/100/500/1000 tablets per bottle  
and 10 X 10 unitdose blisters

**Revision No.:** 02

the exposure limits listed above in this section.

### Section 9. Physical and chemical properties

<b>Appearance</b>	Donepezil Hydrochloride Orally disintegrating Tablets, <b>5 mg</b> are white to off-white, round-shaped, biconvex, uncoated tablets engraved with 'ZF 14' on one side and plain on other side Donepezil Hydrochloride Orally Disintegrating Tablets, <b>10 mg</b> are white to off-white, round-shaped, biconvex, uncoated tablets engraved with 'ZF 15' on one side and plain on other side		
<b>Solubility</b>	soluble in chloroform, water and methanol; sparingly soluble in acetic acid.	<b>Odour</b>	No Data Available
<b>Boiling point</b>	No Data Available	<b>Melting Point</b>	No Data Available
<b>Evaporation rate</b>	No Data Available	<b>Vapour density</b>	No Data Available
<b>Reactivity in water</b>	No Data Available	<b>Evaporation rate</b>	No Data Available
<b>Percentage Volatile by volume</b>	No Data Available	<b>Specific gravity</b>	No Data Available
<b>Vapour pressure</b>	No Data Available		
<b>Other information</b>	Not Applicable		

### Section 10. Stability and Reactivity

<b>Condition to avoid</b>	Avoid exposure to extreme heat, light and moisture.	<b>Stable</b>	Stable under normal ambient and anticipated storage and handling conditions.
<b>Decomposition Products</b>	No Data Available	<b>Hazardous Reaction</b>	No data available.
<b>Incompatibilities</b>	No data available.		

### Section 11. Toxicological information

<b>General</b>	Handling of formulated product is not expected to cause any toxicological affects. The data pertains to the ingredient in
----------------	---

**Safety Data Sheet**  
**Donepezil Hydrochloride Orally Disintegrating Tablets**

**Strength:** 5 mg and 10 mg **Pack Size:** 30/90/100/500/1000 tablets per bottle  
and 10 X 10 unitdose blisters

**Revision No.:** 02

---

formulations, rather than this specie formulation.

**Target organ** Eye contact, Skin contact and inhalation is not great risk as this product is tablet.

**Other** Not Applicable

**Section 12. Ecological information**

Do not allow product to enter drinking water supplies, waste water or soil

**Section 13. Disposal Consideration**

Dispose the waste in accordance with all applicable Federal, State

**Section 14. Transport Information**

The product is not hazardous when shipping via air (IATA), ground (DOT), or sea(IMDG).

**Section 15. Regulatory Information**

Generic Medicine. Approved by USFDA & the ANDA Number is 090175

**Section 16. Other information**

None

**Date of issue:** 28/05/2015

**Supersedes edition of:** 01

The information contained herein is based on the state of our knowledge. It Characterises the product with regard to the appropriate safety precautions. It does not represent a guarantee of the properties of the product.